Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy

seekingalpha06-08

Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441500099?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325625958/image_1325625958.jpg","is_english":true,"pubTime":"2024-06-08 00:46","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2441500099","market":"sh","top_or_hot":-1,"title":"Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy","media":"seekingalpha","content":"<div>\n<p>Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic...</p>\n\n<a href=\"https://seekingalpha.com/news/4114201-arcturus-stock-falls-cystic-fibrosis-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcturus falls after detailed Phase 1 data for cystic fibrosis therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-08 00:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4114201-arcturus-stock-falls-cystic-fibrosis-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic...</p>\n\n<a href=\"https://seekingalpha.com/news/4114201-arcturus-stock-falls-cystic-fibrosis-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4114201-arcturus-stock-falls-cystic-fibrosis-data","article_id":"2441500099","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325625958/image_1325625958.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441500099","pubTimestamp":1717778771,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Arcturus Therapeutics  traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic fibrosis. The stock rallied last week in reaction to early data from the study posted ahead of a presentation at the European Cystic Fibrosis Conference on Friday. The readout represented 36 study participants, including four adults with cystic fibrosis who received ARCT-032 as part of a Phase 1b trial. Following the event, based on eight-day interim data from the Phase 1b trial, Arcturus  said ARCT-032, on average, led to a nearly 6% relative change in FEV1 , a metric used to measure lung function in cystic fibrosis. The company noted that patients and healthy individuals in the early-stage trials didn’t develop severe adverse events linked to the drug. It added that ARCT-032, an inhaled messenger-RNA-based therapy, was generally safe and well tolerated.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARCT":"Arcturus Therapeutics Ltd."},"translate_title":"Arcturus在囊性纤维化治疗的详细1期数据后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARCT":1},"content_text":"Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic fibrosis. The stock rallied last week in reaction to early data from the study posted ahead of a presentation at the European Cystic Fibrosis Conference on Friday. The readout represented 36 study participants, including four adults with cystic fibrosis who received ARCT-032 as part of a Phase 1b trial. Following the event, based on eight-day interim data from the Phase 1b trial, Arcturus (ARCT) said ARCT-032, on average, led to a nearly 6% relative change in FEV1 (forced expiratory volume in 1 second), a metric used to measure lung function in cystic fibrosis. The company noted that patients and healthy individuals in the early-stage trials didn’t develop severe adverse events linked to the drug. It added that ARCT-032, an inhaled messenger-RNA-based therapy, was generally safe and well tolerated.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441500099"}